- Sirdaryo viloyati Guliston shahar
- Dushanba-Shanba: 9.00 - 18.00
Tuxtayeva Nigora Xasanovna
Xasanov Qobil Hakimovich
Kodirova Irodakhon Ilyaskhanovna
Sultonova Dinora Kambarovna
10.5281/zenodo.22938815
Annotatsiya
Podagra — dunyoda eng keng tarqalgan yallig‘lanishli artrit bo‘lib, global sog‘liqni saqlash muammosining o‘sib borayotgan shaklidir. U purin almashinuvi buzilishi natijasida yuzaga kelgan giperurikemiya tufayli rivojlanadi, bu esa mononatriy urat (MNU) kristallarining cho‘kishi va takrorlanuvchi yallig‘lanishli artritga olib keladi. Giperurikemiya asosiy xavf omili bo‘lsa-da, genetik moyillik, urat transportining buzilishi va ichak mikrobiotasi kabi yangi omillar ham kasallik rivojlanishiga hissa qo‘shadi. O‘tkir zo‘rayishlar MNU kristallari tomonidan chaqirilgan NLRP3 inflammasomasining faollashuvi va keyinchalik interleykin-1β ishlab chiqarilishi orqali amalga oshadi, surunkali
yallig‘lanish esa tofuslar hosil bo‘lishi va bo‘g‘imlarning strukturaviy shikastlanishiga olib
keladi. Podagra metabolik sindrom, surunkali buyrak kasalligi va yurak-qon tomir
kasalliklari bilan chambarchas bog‘liq bo‘lib, ular doimiy ravishda oshgan o‘limga hissa
qo‘shadi. Vizualizatsiya va farmakologik terapiya sohasidagi yutuqlar tashxis va davolashni
yaxshilagan bo‘lsa-da, urat pasaytiruvchi terapiyaning real amaliyotda qo‘llanilishi hali ham
optimal emas. Kasallikni uzoq muddatli nazorat qilishni yaxshilash uchun qo‘shimcha
tadqiqotlar va tibbiyot xodimlarining doimiy sa’y-harakatlari zarur.
Kalit so'zlar:
Medikamentoz terapiya, podagra, giperurikemiya, metabolik
kasalliklar, siydik kislotasi.
Foydalanilgan adabiyotlar
1. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020;16:380–90. 2. Zhang S, Wang Y, Cheng J, Huangfu N, Zhao R, Xu Z, et al. Hyperuricemia and cardiovascular disease. Curr Pharm Des 2019;25:700–9. 3. McCormick N, Lin K, Yokose C, Lu N, Zhang Y, Choi HK. Unclosing premature mortality gap among patients with gout in the US general population, independent of serum urate and atherosclerotic cardiovascular risk factors. Arthritis Care Res (Hoboken) 2024;76:691–702. 4. Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum 2020;50:S11–6. 5. Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis 2010;68:199–203. 6. Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther 2024;9:212. 7. Punjwani S, Jani C, Liu W, Kakoullis L, Salciccioli I, Al Omari O, et al. Burden of gout among different WHO regions, 1990-2019: estimates from the global burden of disease study. Sci Rep 2024;14:15953. 8. Yokose C, McCormick N, Lu N, Tanikella S, Lin K, Joshi AD, et al. Trends in prevalence of gout among US Asian adults, 2011-2018. JAMA Netw Open 2023;6:e239501. 9. Ahn JK. Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean. J Rheum Dis 2023;30:88–98. 10. Health Insurance Review & Assessment Service. Medical care expenditure statistical indicators for the first half of 2023 [Internet]. Health Insurance Review & Assessment Service. 11. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin Rheumatol 2018;37:2529–38. 12. Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis 2018;77:1048–52. 13. Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012;8:610–21. 14. Lyngdoh T, Vuistiner P, Marques-Vidal P, Rousson V, Waeber G, Vollenweider P, et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One 2012;7:e39321. 15. Choi HK, McCormick N, Lu N, Rai SK, Yokose C, Zhang Y. Population impact attributable to modifiable risk factors for hyperuricemia. Arthritis Rheumatol 2020;72:157 65.